Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Celldex Therapeutics Inc
SWB:TCE2
Celldex Therapeutics Inc
SWB:TCE2
Price:
36.02
EUR
2.24%
Market Closed
Market Cap:
€1.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Celldex Therapeutics Inc
SWB:TCE2
|
US |
|
M3 Metals Corp
XTSX:MT
|
CA |
|
G
|
Gem Diamonds Ltd
OTC:GMDMF
|
UK |
|
S
|
Slide Insurance Holdings Inc
NASDAQ:SLDE
|
US |
|
Xinyi Solar Holdings Ltd
F:13X0
|
CN |
|
Trigano SA
OTC:TGNOF
|
FR |
|
H
|
Huazhu Group Ltd
NASDAQ:HTHT
|
CN |
|
Aucnet Inc
TSE:3964
|
JP |
|
Multipolar Tbk PT
F:MLQ2
|
ID |
|
P
|
Princeton Technology Corp
TPEX:6129
|
TW |
|
F
|
FN Factory Outlet PCL
SET:FN
|
TH |
|
H
|
Hyundai BioLand Co Ltd
KOSDAQ:052260
|
KR |
|
Z
|
Zoetis Inc
F:ZOE
|
US |
|
Tali Digital Ltd
ASX:TD1
|
AU |
|
K
|
Kingstate Electronics Corp
TPEX:3206
|
TW |
|
Petronor E&P ASA
F:FQ00
|
NO |
|
P
|
Penta Valent Tbk PT
IDX:PEVE
|
ID |
Wall St Price Targets
TCE2 Price Forecast
Based on 16 analysts
Based on 16 analysts
+60% Upside
from
€36.02
today
Celldex Therapeutics Inc (TCE2)’s 12-month stock price forecast through August 2027 has a consensus target of €57.65, implying 60% upside. The forecast is based on price targets from 16 Wall Street analysts.
TCE2 Analyst Rating
No ratings yet
No ratings yet
Celldex Therapeutics Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is TCE2's stock price target?
Price Target
57.65
EUR
57.65
EUR
According to Wall Street analysts, the average 1-year price target for TCE2 is 57.65 EUR with a low forecast of 24.97 EUR and a high forecast of 92.72 EUR.
What is the Revenue forecast for Celldex Therapeutics Inc?
Projected CAGR
147%
147%
Over the last 13 years, the compound annual growth rate for Revenue has been -14%. The projected CAGR for the next 8 years is 147%.